Search

Your search keyword '"Admon, Arie"' showing total 577 results
Start Over Author "Admon, Arie"
577 results on '"Admon, Arie"'

4. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* [S]

Author

Shraibman, Bracha, Barnea, Eilon, Kadosh, Dganit Melamed, Haimovich, Yael, Slobodin, Gleb, Rosner, Itzhak, López-Larrea, Carlos, Hilf, Norbert, Kuttruff, Sabrina, Song, Colette, Britten, Cedrik, Castle, John, Kreiter, Sebastian, Frenzel, Katrin, Tatagiba, Marcos, Tabatabai, Ghazaleh, Dietrich, Pierre-Yves, Dutoit, Valérie, Wick, Wolfgang, Platten, Michael, Winkler, Frank, von Deimling, Andreas, Kroep, Judith, Sahuquillo, Juan, Martinez-Ricarte, Francisco, Rodon, Jordi, Lassen, Ulrik, Ottensmeier, Christian, van der Burg, Sjoerd H, Thor Straten, Per, Poulsen, Hans Skovgaard, Ponsati, Berta, Okada, Hideho, Rammensee, Hans-Georg, Sahin, Ugur, Singh, Harpreet, and Admon, Arie

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Rare Diseases, Brain Disorders, Neurosciences, Brain Cancer, Cancer, Good Health and Well Being, Alleles, Antigens, Neoplasm, Biomarkers, Tumor, Brain Neoplasms, Glioblastoma, Histocompatibility Antigens Class I, Humans, Peptides, Proteome, CTA, Cancer Biomarker(s), Cancer Therapeutics, HLA, Immunoaffinity, Immunotherapy, MHC, Peptidomics, Plasma or Serum Analysis, Biochemistry & Molecular Biology
Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Further, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.

Published
2019

6. Identification of bacteria-derived HLA-bound peptides in melanoma

Author

Kalaora, Shelly, Nagler, Adi, Nejman, Deborah, Alon, Michal, Barbolin, Chaya, Barnea, Eilon, Ketelaars, Steven L. C., Cheng, Kuoyuan, Vervier, Kevin, Shental, Noam, Bussi, Yuval, Rotkopf, Ron, Levy, Ronen, Benedek, Gil, Trabish, Sophie, Dadosh, Tali, Levin-Zaidman, Smadar, Geller, Leore T., Wang, Kun, Greenberg, Polina, Yagel, Gal, Peri, Aviyah, Fuks, Garold, Bhardwaj, Neerupma, Reuben, Alexandre, Hermida, Leandro, Johnson, Sarah B., Galloway-Peña, Jessica R., Shropshire, William C., Bernatchez, Chantale, Haymaker, Cara, Arora, Reetakshi, Roitman, Lior, Eilam, Raya, Weinberger, Adina, Lotan-Pompan, Maya, Lotem, Michal, Admon, Arie, Levin, Yishai, Lawley, Trevor D., Adams, David J., Levesque, Mitchell P., Besser, Michal J., Schachter, Jacob, Golani, Ofra, Segal, Eran, Geva-Zatorsky, Naama, Ruppin, Eytan, Kvistborg, Pia, Peterson, Scott N., Wargo, Jennifer A., Straussman, Ravid, and Samuels, Yardena

Published
2021
Full Text
View/download PDF

8. Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination

Author

Braten, Ori, Livneh, Ido, Ziv, Tamar, Admon, Arie, Kehat, Izhak, Caspi, Lilac H, Gonen, Hedva, Bercovich, Beatrice, Godzik, Adam, Jahandideh, Samad, Jaroszewski, Lukasz, Sommer, Thomas, Kwon, Yong Tae, Guharoy, Mainak, Tompa, Peter, and Ciechanover, Aaron

Subjects
1.1 Normal biological development and functioning, Underpinning research, Generic health relevance, Humans, MCF-7 Cells, Proteasome Endopeptidase Complex, Proteins, Proteomics, Ubiquitination, monoubiquitination, 26S proteasome, protein degradation, ubiquitin replacement
Abstract

The "canonical" proteasomal degradation signal is a substrate-anchored polyubiquitin chain. However, a handful of proteins were shown to be targeted following monoubiquitination. In this study, we established-in both human and yeast cells-a systematic approach for the identification of monoubiquitination-dependent proteasomal substrates. The cellular wild-type polymerizable ubiquitin was replaced with ubiquitin that cannot form chains. Using proteomic analysis, we screened for substrates that are nevertheless degraded under these conditions compared with those that are stabilized, and therefore require polyubiquitination for their degradation. For randomly sampled representative substrates, we confirmed that their cellular stability is in agreement with our screening prediction. Importantly, the two groups display unique features: monoubiquitinated substrates are smaller than the polyubiquitinated ones, are enriched in specific pathways, and, in humans, are structurally less disordered. We suggest that monoubiquitination-dependent degradation is more widespread than assumed previously, and plays key roles in various cellular processes.

Published
2016

9. TGFβ signaling pathway is altered by HLA-B27 expression, resulting in pathogenic consequences relevant for spondyloarthritis.

Author

Lauraine, Marc, primary, De Tilques, Maxence De Taffin, additional, Melamed-Kadosh, Dganit, additional, Cherqaoui, Bilade, additional, Rincheval, Vincent, additional, Prevost, Erwann, additional, Rincheval-Arnold, Aurore, additional, Cela, Eneida, additional, Admon, Arie, additional, Guénal, Isabelle, additional, Araujo, Luiza, additional, and Breban, Maxime, additional

Published
2023
Full Text
View/download PDF

12. Actively personalized vaccination trial for newly diagnosed glioblastoma

Author

Hilf, Norbert, Kuttruff-Coqui, Sabrina, Frenzel, Katrin, Bukur, Valesca, Stevanović, Stefan, Gouttefangeas, Cécile, Platten, Michael, Tabatabai, Ghazaleh, Dutoit, Valerie, van der Burg, Sjoerd H., thor Straten, Per, Martínez-Ricarte, Francisco, Ponsati, Berta, Okada, Hideho, Lassen, Ulrik, Admon, Arie, Ottensmeier, Christian H., Ulges, Alexander, Kreiter, Sebastian, von Deimling, Andreas, Skardelly, Marco, Migliorini, Denis, Kroep, Judith R., Idorn, Manja, Rodon, Jordi, Piró, Jordi, Poulsen, Hans S., Shraibman, Bracha, McCann, Katy, Mendrzyk, Regina, Löwer, Martin, Stieglbauer, Monika, Britten, Cedrik M., Capper, David, Welters, Marij J. P., Sahuquillo, Juan, Kiesel, Katharina, Derhovanessian, Evelyna, Rusch, Elisa, Bunse, Lukas, Song, Colette, Heesch, Sandra, Wagner, Claudia, Kemmer-Brück, Alexandra, Ludwig, Jörg, Castle, John C., Schoor, Oliver, Tadmor, Arbel D., Green, Edward, Fritsche, Jens, Meyer, Miriam, Pawlowski, Nina, Dorner, Sonja, Hoffgaard, Franziska, Rössler, Bernhard, Maurer, Dominik, Weinschenk, Toni, Reinhardt, Carsten, Huber, Christoph, Rammensee, Hans-Georg, Singh-Jasuja, Harpreet, Sahin, Ugur, Dietrich, Pierre-Yves, and Wick, Wolfgang

Published
2019
Full Text
View/download PDF

18. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma

Author

Peri, Aviyah, Greenstein, Erez, Alon, Michal, Pai, Joy A., Dingjan, Tamir, Reich- Zeliger, Shlomit, Barnea, Eilon, Barbolin, Chaya, Levy, Ronen, Arnedo-Pac, Claudia, Kalaora, Shelly, Dassa, Bareket, Feldmesser, Ester, Shang, Ping, Greenberg, Polina, Levin, Yishai, Benedek, Gil, Levesque, Mitchell P., Adams, David J., Lotem, Michal, Wilmott, James S., Scolyer, Richard A., Jonsson, Goran B., Admon, Arie, Rosenberg, Steven A., Cohen, Cyrille J., Niv, Masha Y., Lopez- Bigas, Nuria, Satpathy, Ansuman T., Friedman, Nir, and Samuels, Yardena

Subjects
HLA histocompatibility antigens -- Identification and classification -- Genetic aspects, Immune response -- Genetic aspects, Tumor antigens -- Genetic aspects -- Identification and classification, Melanoma -- Diagnosis -- Genetic aspects, Histocompatibility antigens -- Identification and classification -- Genetic aspects, Guanosine triphosphatase -- Genetic aspects -- Health aspects, Health care industry
Abstract

Neoantigens are now recognized drivers of the antitumor immune response. Recurrent neoantigens, shared among groups of patients, have thus become increasingly coveted therapeutic targets. Here, we report on the data-driven identification of a robustly presented, immunogenic neoantigen that is derived from the combination of HLA-A*01:01 and RAS.Q61K. Analysis of large patient cohorts indicated that this combination applies to 3% of patients with melanoma. Using HLA peptidomics, we were able to demonstrate robust endogenous presentation of the neoantigen in 10 tumor samples. We detected specific reactivity to the mutated peptide within tumor-infiltrating lymphocytes (TILs) from 2 unrelated patients, thus confirming its natural immunogenicity. We further investigated the neoantigen-specific clones and their T cell receptors (TCRs) via a combination of TCR sequencing, TCR overexpression, functional assays, and single-cell transcriptomics. Our analysis revealed a diverse repertoire of neoantigen-specific clones with both intra- and interpatient TCR similarities. Moreover, 1 dominant clone proved to cross-react with the highly prevalent RAS.Q61R variant. Transcriptome analysis revealed a high association of TCR clones with specific T cell phenotypes in response to cognate melanoma, with neoantigen-specific cells showing an activated and dysfunctional phenotype. Identification of recurrent neoantigens and their reactive TCRs can promote 'off-the-shelf' precision immunotherapies, alleviating limitations of personalized treatments., Introduction Immunotherapy sparked new hope for oncology in recent years, due to its remarkable ability to induce long-term tumor regression of metastatic cancer. This feature is shared across immunotherapeutic modalities, [...]

Published
2021
Full Text
View/download PDF

20. Supplementary Movies 7-9 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Movies 4-6 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

22. Data from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Movies 1-3 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

24. Supplementary methods from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Tables 1, 2, 4, 5, 8, 10, 13, 14, 15 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Tables 3, 6, 7, 9, 11, 12 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures 1-17 from Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Author

Kalaora, Shelly, primary, Wolf, Yochai, primary, Feferman, Tali, primary, Barnea, Eilon, primary, Greenstein, Erez, primary, Reshef, Dan, primary, Tirosh, Itay, primary, Reuben, Alexandre, primary, Patkar, Sushant, primary, Levy, Ronen, primary, Quinkhardt, Juliane, primary, Omokoko, Tana, primary, Qutob, Nouar, primary, Golani, Ofra, primary, Zhang, Jianhua, primary, Mao, Xizeng, primary, Song, Xingzhi, primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Forget, Marie-Andrée, primary, Creasy, Caitlin, primary, Greenberg, Polina, primary, Carter, Brett W., primary, Cooper, Zachary A., primary, Rosenberg, Steven A., primary, Lotem, Michal, primary, Sahin, Ugur, primary, Shakhar, Guy, primary, Ruppin, Eytan, primary, Wargo, Jennifer A., primary, Friedman, Nir, primary, Admon, Arie, primary, and Samuels, Yardena, primary

Published
2023
Full Text
View/download PDF

32. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors

Author

Kacen, Assaf, primary, Javitt, Aaron, additional, Kramer, Matthias P., additional, Morgenstern, David, additional, Tsaban, Tomer, additional, Shmueli, Merav D., additional, Teo, Guo Ci, additional, da Veiga Leprevost, Felipe, additional, Barnea, Eilon, additional, Yu, Fengchao, additional, Admon, Arie, additional, Eisenbach, Lea, additional, Samuels, Yardena, additional, Schueler-Furman, Ora, additional, Levin, Yishai, additional, Nesvizhskii, Alexey I., additional, and Merbl, Yifat, additional

Published
2022
Full Text
View/download PDF

35. Chemical inhibition of ER aminopeptidase 1 as a tool for regulating the immunopeptidome of cancer cells

Author

Koumantou, Despoina, primary, Barnea, Eilon, additional, Martin-Esteban, Adrian, additional, Maben, Zachary, additional, Papakyriakou, Athanasios, additional, Kokkala, Paraskevi, additional, Pratsinis, Harris, additional, Georgiadis, Dimitris, additional, Stern, Lawrence J., additional, Admon, Arie, additional, and Stratikos, Efstratios, additional

Published
2022
Full Text
View/download PDF

44. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Author

Hilf, Norbert, Kuttruff-Coqui, Sabrina, Frenzel, Katrin, Bukur, Valesca, Stevanović, Stefan, Gouttefangeas, Cecile, Platten, Michael, Tabatabai, Ghazaleh, Dutoit, Valerie, van der Burg, Sjoerd H., Straten, Per thor, Martinez-Ricarte, Francisco, Ponsati, Berta, Okada, Hideho, Lassen, Ulrik, Admon, Arie, Ottensmeier, Christian H., Ulges, Alexander, Kreiter, Sebastian, von Deimling, Andreas, Skardelly, Marco, Migliorini, Denis, Kroep, Judith R., Idorn, Manja, Rodon, Jordi, Piro, Jordi, Poulsen, Hans S., Shraibman, Bracha, McCann, Katy, Mendrzyk, Regina, Lower, Martin, Stieglbauer, Monika, Britten, Cedrik M., Capper, David, Welters, Marij J. P., Sahuquillo, Juan, Kiesel, Katharina, Derhovanessian, Evelyna, Rusch, Elisa, Bunse, Lukas, Song, Colette, Heesch, Sandra, Wagner, Claudia, Kemmer-Bruck, Alexandra, Ludwig, Jorg, Castle, John C., Schoor, Oliver, Tadmor, Arbel D., Green, Edward, Fritsche, Jens, Meyer, Miriam, Pawlowski, Nina, Dorner, Sonja, Hoffgaard, Franziska, Rossler, Bernhard, Maurer, Dominik, Weinschenk, Toni, Reinhardt, Carsten, Huber, Christoph, Rammensee, Hans-Georg, Singh-Jasuja, Harpreet, Sahin, Ugur, Dietrich, Pierre-Yves, and Wick, Wolfgang

Published
2019
Full Text
View/download PDF

45. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens

Author

Khazan-Kost, Sofia, primary, Cafri, Gal, additional, Melamed Kadosh, Dganit, additional, Mooshayef, Navit, additional, Chatterji, Sumit, additional, Dominissini, Dan, additional, Manor, Sigal, additional, Zisser, Bracha, additional, Broday, Limor, additional, Talalai, Efrosiniia, additional, Shemer, Anat, additional, Zadok, Oranit, additional, Ofek, Efrat, additional, Onn, Amir, additional, Admon, Arie, additional, and Peled, Michael, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results